Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

2018 Korean Guideline of Atrial Fibrillation Management

  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Lee, Jung Myung (Division of Cardiology, Department of Internal Medicine, Kyung Hee University Medical College) ;
  • Lee, Ki Hong (Department of Cardiology, Chonnam National University Hospital) ;
  • Kim, Tae-Hoon (Division of Cardiology, Department of Internal Medicine, Kyung Hee University Medical College) ;
  • Choi, Eue-Keun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lim, Woo-Hyun (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kang, Ki-Woon (Division of Cardiology, Eulji University College of Medicine) ;
  • Shim, Jaemin (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Lim, Hong Euy (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Park, Junbeom (Department of Cardiology, Ewha Woman University) ;
  • Lee, So-Ryoung (Division of Cardiology, Department of Internal Medicine, Soon Chun Hyang University Hospital) ;
  • Lee, Young Soo (Division of Cardiology, Department of Internal Medicine, Daegu Catholic University) ;
  • Kim, Jin-Bae (Division of Cardiology, Department of Internal Medicine, Kyung Hee University Medical College) ;
  • KHRS Atrial Fibrillation Guideline Working Group (KHRS)
  • Received : 2018.09.27
  • Accepted : 2018.10.08
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population. The Korean Heart Rhythm Society organized a Korean AF Management Guideline Committee and analyzed all available studies regarding the management of AF, including studies on Korean patients. This guideline is based on recent data of the Korean population and the recent guidelines of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery, American Heart Association, and Asia Pacific Heart Rhythm Society. Expert consensus or guidelines for the optimal management of Korean patients with AF were achieved after a systematic review with intensive discussion. This article provides general principles for appropriate risk stratification and selection of anticoagulation therapy in Korean patients with AF. This guideline deals with optimal stroke prevention, screening, rate and rhythm control, risk factor management, and integrated management of AF.

Keywords

Acknowledgement

Supported by : Ministry of Health & Welfare

References

  1. Jones C, Pollit V, Fitzmaurice D, Cowan C; Guideline Development Group. The management of atrial fibrillation: summary of updated NICE guidance. BMJ 2014;348:g3655. https://doi.org/10.1136/bmj.g3655
  2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-76. https://doi.org/10.1016/j.jacc.2014.03.022
  3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962. https://doi.org/10.1093/eurheartj/ehw210
  4. Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm 2017;33:345-67. https://doi.org/10.1016/j.joa.2017.05.004
  5. Lip GY, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018 [Epub ahead of print].
  6. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52. https://doi.org/10.1161/01.CIR.98.10.946
  7. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199-267.
  8. Lee H, Kim TH, Baek YS, et al. The trends of atrial fibrillation-related hospital visit and cost, treatment pattern and mortality in Korea: 10-year nationwide sample cohort data. Korean Circ J 2017;47:56-64. https://doi.org/10.4070/kcj.2016.0045
  9. Kim TH, Yang PS, Uhm JS, et al. CHA2DS2-VASc score (congestive heart failure, hypertension, age${\geq}$75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study. Stroke 2017;48:1524-30. https://doi.org/10.1161/STROKEAHA.117.016926
  10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-64. https://doi.org/10.1016/S0002-9343(02)01236-6
  11. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5. https://doi.org/10.1001/jama.285.18.2370
  12. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140
  13. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746-51. https://doi.org/10.1093/eurheartj/eht280
  14. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-56. https://doi.org/10.1111/j.1524-4733.2006.00124.x
  15. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92. https://doi.org/10.1136/hrt.2002.008748
  16. Li Y, Pastori D, Guo Y, Wang Y, Lip GY. Risk factors for new-onset atrial fibrillation: a focus on Asian populations. Int J Cardiol 2018;261:92-8. https://doi.org/10.1016/j.ijcard.2018.02.051
  17. Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost 2017;117:837-50. https://doi.org/10.1160/TH16-11-0825
  18. Li YG, Pastori D, Farcomeni A, et al. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2018 [Epub ahead of print].
  19. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
  20. Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J 2018;202:20-6. https://doi.org/10.1016/j.ahj.2018.04.017
  21. Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest 2018;153:453-66. https://doi.org/10.1016/j.chest.2017.10.001
  22. Yap KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. J Electrocardiol 2008;41:94-8. https://doi.org/10.1016/j.jelectrocard.2007.03.012
  23. Iguchi Y, Kimura K, Aoki J, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008;72:909-13. https://doi.org/10.1253/circj.72.909
  24. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol 2017;236:226-31. https://doi.org/10.1016/j.ijcard.2017.02.039
  25. Yang PS, Ryu S, Kim D, et al. Variations of prevalence and incidence of atrial fibrillation and oral anticoagulation rate according to different analysis approaches. Sci Rep 2018;8:6856. https://doi.org/10.1038/s41598-018-25111-6
  26. Yang PS, Joung B. Regional and socioeconomic inequality of atrial fibrillation with regular hospital visit. Korean Circ J 2018;48:635-6. https://doi.org/10.4070/kcj.2018.0116
  27. Lee SR, Choi EK, Han K, Cha MJ, Oh S. Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the entire Korean population. Korean Circ J 2018;48:622-34. https://doi.org/10.4070/kcj.2017.0362
  28. Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018 [Epub ahead of print].
  29. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20. https://doi.org/10.1161/CIRCOUTCOMES.110.958165
  30. Lee WC, Lamas GA, Balu S, Spalding J, Wang Q, Pashos CL. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ 2008;11:281-98. https://doi.org/10.3111/13696990802063425
  31. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:1268-75. https://doi.org/10.1016/j.jacc.2004.06.029
  32. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818-28. https://doi.org/10.1016/S0140-6736(16)31258-2
  33. Schmidt M, Ulrichsen SP, Pedersen L, Botker HE, Nielsen JC, Sorensen HT. 30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. Int J Cardiol 2016;225:30-6. https://doi.org/10.1016/j.ijcard.2016.09.071
  34. Schmidt M, Jacobsen JB, Johnsen SP, Botker HE, Sorensen HT. Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity. Neurology 2014;82:340-50. https://doi.org/10.1212/WNL.0000000000000062
  35. Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation 2017;135:1851-67. https://doi.org/10.1161/CIRCULATIONAHA.116.026693
  36. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017;19:1589-623. https://doi.org/10.1093/europace/eux177
  37. Arya A, Piorkowski C, Sommer P, Kottkamp H, Hindricks G. Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2007;30:458-62. https://doi.org/10.1111/j.1540-8159.2007.00693.x
  38. Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012;14:1553-9. https://doi.org/10.1093/europace/eus087
  39. Siontis KC, Gersh BJ, Killian JM, et al. Typical, atypical, and asymptomatic presentations of newonset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm 2016;13:1418-24. https://doi.org/10.1016/j.hrthm.2016.03.003
  40. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22. https://doi.org/10.1160/TH13-02-0165
  41. Boriani G, Laroche C, Diemberger I, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509-518.e2. https://doi.org/10.1016/j.amjmed.2014.11.026
  42. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013;168:4744-9. https://doi.org/10.1016/j.ijcard.2013.07.234
  43. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii-iv.
  44. Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015;17:1023-9. https://doi.org/10.1093/europace/euv083
  45. Levin LA, Husberg M, Sobocinski PD, et al. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace 2015;17:207-14. https://doi.org/10.1093/europace/euu213
  46. Son MK, Lim NK, Park HY. Trend of prevalence of atrial fibrillation and use of oral anticoagulation therapy in patients with atrial fibrillation in South Korea (2002-2013). J Epidemiol 2018;28:81-7. https://doi.org/10.2188/jea.JE20160149
  47. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-yearold population: implications for stroke prevention. Circulation 2013;127:930-7. https://doi.org/10.1161/CIRCULATIONAHA.112.126656
  48. Halcox JP, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: the REHEARSE-AF Study. Circulation 2017;136:1784-94. https://doi.org/10.1161/CIRCULATIONAHA.117.030583
  49. Chan NY, Choy CC, Chan CK, Siu CW. Effectiveness of a nongovernmental organization-led largescale community atrial fibrillation screening program using the smartphone electrocardiogram: an observational cohort study. Heart Rhythm 2018;15:1306-11. https://doi.org/10.1016/j.hrthm.2018.06.006
  50. Healey JS, Alings M, Ha A, et al. Subclinical atrial fibrillation in older patients. Circulation 2017;136:1276-83. https://doi.org/10.1161/CIRCULATIONAHA.117.028845
  51. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-9. https://doi.org/10.1161/01.CIR.0000057981.70380.45
  52. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-9. https://doi.org/10.1056/NEJMoa1105575
  53. Van Gelder IC, Healey JS, Crijns HJ, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017;38:1339-44. https://doi.org/10.1093/eurheartj/ehx042
  54. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141-7. https://doi.org/10.1161/CIRCEP.109.877852
  55. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094-9. https://doi.org/10.1161/CIRCULATIONAHA.113.007825
  56. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-80. https://doi.org/10.1161/CIRCEP.109.849638
  57. Santini M, Gasparini M, Landolina M, et al. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011;57:167-72. https://doi.org/10.1016/j.jacc.2010.08.624
  58. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35:508-16. https://doi.org/10.1093/eurheartj/eht491
  59. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016;388:806-17. https://doi.org/10.1016/S0140-6736(16)31257-0
  60. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605. https://doi.org/10.1161/STROKEAHA.114.006070
  61. Perera KS, Vanassche T, Bosch J, et al. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry. Stroke 2016;47:2197-202. https://doi.org/10.1161/STROKEAHA.116.013378
  62. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015;14:377-87. https://doi.org/10.1016/S1474-4422(15)70027-X
  63. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41. https://doi.org/10.1161/01.STR.24.1.35
  64. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-77. https://doi.org/10.1056/NEJMoa1311376
  65. Thijs VN, Brachmann J, Morillo CA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology 2016;86:261-9. https://doi.org/10.1212/WNL.0000000000002282
  66. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GY. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway. Am J Med. 2018 [Epub ahead of print].
  67. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013;9:123-7. https://doi.org/10.2174/1573403X11309020005
  68. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-62. https://doi.org/10.1016/S0140-6736(14)61774-8
  69. Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016;18:12-36. https://doi.org/10.1093/europace/euv191
  70. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-307. https://doi.org/10.1016/j.jacc.2010.01.043
  71. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. https://doi.org/10.1016/j.jacc.2004.11.070
  72. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the reninangiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43. https://doi.org/10.1097/MJT.0b013e31804beb59
  73. Kotecha D, Holmes J, Krum H, et al. Efficacy of ${\beta}$ blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-43. https://doi.org/10.1016/S0140-6736(14)61373-8
  74. Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012;59:1598-603. https://doi.org/10.1016/j.jacc.2011.11.063
  75. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-27. https://doi.org/10.1056/NEJMoa1707855
  76. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012;30:239-52. https://doi.org/10.1097/HJH.0b013e32834f03bf
  77. Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 2018;72:1233-45. https://doi.org/10.1016/j.jacc.2018.05.076
  78. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-14. https://doi.org/10.1093/eurheartj/eht507
  79. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9. https://doi.org/10.1016/j.jacc.2004.10.068
  80. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-6. https://doi.org/10.1161/01.CIR.0000022665.18619.83
  81. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-8. https://doi.org/10.1016/j.ehj.2003.08.014
  82. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006;152:217-22. https://doi.org/10.1016/j.ahj.2006.01.007
  83. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-35. https://doi.org/10.1093/eurheartj/ehp055
  84. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-8. https://doi.org/10.1016/j.jacc.2012.06.030
  85. Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015;29:88-92. https://doi.org/10.1016/j.jdiacomp.2014.09.002
  86. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol 2015;26:223-5. https://doi.org/10.1111/jce.12560
  87. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:1217-22. https://doi.org/10.1016/j.amjcard.2014.07.045
  88. Fangel MV, Nielsen PB, Larsen TB, et al. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. Int J Cardiol 2018;268:137-42. https://doi.org/10.1016/j.ijcard.2018.05.037
  89. Lee SR, Choi EK, Rhee TM, et al. Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: a nationwide population-based study. Int J Cardiol 2016;223:953-7. https://doi.org/10.1016/j.ijcard.2016.08.296
  90. Lip GY. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627-8. https://doi.org/10.1038/nrcardio.2017.153
  91. Mazurek M, Shantsila E, Lane DA, Wolff A, Proietti M, Lip GY. Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation: insights from the community-based Darlington atrial fibrillation registry. Mayo Clin Proc 2017;92:1203-13. https://doi.org/10.1016/j.mayocp.2017.05.023
  92. Proietti M, Nobili A, Raparelli V, et al. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol 2016;105:912-20. https://doi.org/10.1007/s00392-016-0999-4
  93. Ancedy Y, Lecoq C, Saint Etienne C, et al. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: what is the impact of guideline adherence? Int J Cardiol 2016;203:987-94. https://doi.org/10.1016/j.ijcard.2015.11.090
  94. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011;140:911-7. https://doi.org/10.1378/chest.10-2436
  95. Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic conditions: the contribution of the ICCC Framework. Health Policy 2012;105:55-64. https://doi.org/10.1016/j.healthpol.2011.10.006
  96. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-9. https://doi.org/10.1001/jama.288.14.1775
  97. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med 2003;26:1-7.
  98. Alonso-Coello P, Montori VM, Sola I, et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res 2008;8:221. https://doi.org/10.1186/1472-6963-8-221
  99. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation 2014;129:704-10. https://doi.org/10.1161/CIRCULATIONAHA.113.004498
  100. Stiggelbout AM, Van der Weijden T, De Wit MP, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012;344:e256. https://doi.org/10.1136/bmj.e256
  101. Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An integrated chronic care program for patients with atrial fibrillation: study protocol and methodology for an ongoing prospective randomised controlled trial. Int J Nurs Stud 2010;47:1310-6. https://doi.org/10.1016/j.ijnurstu.2009.12.017
  102. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GY. Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App Trial. Am J Med 2017;130:1388-1396.e6. https://doi.org/10.1016/j.amjmed.2017.07.003
  103. Lee SS, Ae Kong K, Kim D, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J 2017;38:2599-607. https://doi.org/10.1093/eurheartj/ehx316
  104. Baek YS, Yang PS, Kim TH, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc 2017;6:6.
  105. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4. https://doi.org/10.1001/jama.1994.03510350050036
  106. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7. https://doi.org/10.1001/jama.292.20.2471
  107. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-71. https://doi.org/10.1016/j.jacc.2006.08.060
  108. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 2008;156:1163-9. https://doi.org/10.1016/j.ahj.2008.08.003
  109. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008;300:2489-96. https://doi.org/10.1001/jama.2008.755
  110. Roh SY, Choi JI, Lee JY, et al. Catheter ablation of atrial fibrillation in patients with chronic lung disease. Circ Arrhythm Electrophysiol 2011;4:815-22. https://doi.org/10.1161/CIRCEP.110.960435
  111. Kong KA, Park J, Hong SH, Hong YS, Sung YA, Lee H. Associations between body mass index and mortality or cardiovascular events in a general Korean population. PLoS One 2017;12:e0185024. https://doi.org/10.1371/journal.pone.0185024
  112. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995;123:817-22. https://doi.org/10.7326/0003-4819-123-11-199512010-00001
  113. Hwang JJ, Chen JJ, Lin SC, et al. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol 1993;72:677-81. https://doi.org/10.1016/0002-9149(93)90884-F
  114. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230-9. https://doi.org/10.1160/TH16-11-0876
  115. Kim TH, Shim CY, Park JH, et al. Left ventricular diastolic dysfunction is associated with atrial remodeling and risk or presence of stroke in patients with paroxysmal atrial fibrillation. J Cardiol 2016;68:104-9. https://doi.org/10.1016/j.jjcc.2015.10.008
  116. Yu HT, Yang PS, Lee H, et al. Outcomes of rate-control treatment in patients with atrial fibrillation and heart failure: a nationwide cohort study. Circ J 2018;82:652-8. https://doi.org/10.1253/circj.CJ-17-0669
  117. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J 2007;153:1006-12. https://doi.org/10.1016/j.ahj.2007.03.008
  118. Stock S, Pitcavage JM, Simic D, et al. Chronic care model strategies in the United States and Germany deliver patient-centered, high-quality diabetes care. Health Aff (Millwood) 2014;33:1540-8. https://doi.org/10.1377/hlthaff.2014.0428
  119. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
  120. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21. https://doi.org/10.1161/CIRCOUTCOMES.110.958108
  121. Chiang CE, Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010;109:740-73. https://doi.org/10.1016/S0929-6646(10)60120-9
  122. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012;107:1172-9. https://doi.org/10.1160/TH12-03-0175
  123. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013;34:170-6. https://doi.org/10.1093/eurheartj/ehs314
  124. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-65. https://doi.org/10.1016/j.jacc.2014.06.1203
  125. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke 2017;48:2984-90. https://doi.org/10.1161/STROKEAHA.117.018551
  126. Kang SH, Choi EK, Han KD, et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants: Korean nationwide population-based study. Circ J 2017;81:1158-64. https://doi.org/10.1253/circj.CJ-16-1267
  127. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. Atherosclerosis 2011;217:292-5. https://doi.org/10.1016/j.atherosclerosis.2011.03.033
  128. Steensig K, Olesen KK, Thim T, et al. Coronary artery disease is independent risk factor for stroke among patients with atrial fibrillation. J Am Coll Cardiol. 2018 [Epub ahead of print].
  129. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with newonset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56. https://doi.org/10.1001/jama.290.8.1049
  130. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112:1687-91. https://doi.org/10.1161/CIRCULATIONAHA.105.553438
  131. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012;307:1952-8. https://doi.org/10.1001/jama.2012.3490
  132. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012;344:e3522. https://doi.org/10.1136/bmj.e3522
  133. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10:1745-51. https://doi.org/10.1111/j.1538-7836.2012.04853.x
  134. Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GY. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation 2018;137:832-40. https://doi.org/10.1161/CIRCULATIONAHA.117.029081
  135. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014;11:1401-8. https://doi.org/10.1016/j.hrthm.2014.04.021
  136. Guo Y, Apostolakis S, Blann AD, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 2013;168:904-9. https://doi.org/10.1016/j.ijcard.2012.10.052
  137. Tomita H, Okumura K, Inoue H, et al. Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation: subanalysis of the J-RHYTHM registry. Circ J 2015;79:1719-26. https://doi.org/10.1253/circj.CJ-15-0095
  138. Chao TF, Wang KL, Liu CJ, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 2015;66:1339-47. https://doi.org/10.1016/j.jacc.2015.07.026
  139. Kim TH, Yang PS, Yu HT, et al. Age threshold for ischemic stroke risk in atrial fibrillation. Stroke 2018;49:1872-9. https://doi.org/10.1161/STROKEAHA.118.021047
  140. Zulkifly H, Lip GY, Lane DA. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: a review. Heart Rhythm 2018;15:615-23. https://doi.org/10.1016/j.hrthm.2017.11.026
  141. Yoon M, Yang PS, Jang E, et al. Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study. Thromb Haemost 2018;118:1296-304. https://doi.org/10.1055/s-0038-1651482
  142. Chao TF, Lip GY, Liu CJ, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:122-32. https://doi.org/10.1016/j.jacc.2017.10.085
  143. Chao TF, Lip GY, Lin YJ, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018;118:768-77.
  144. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 2015;180:246-54. https://doi.org/10.1016/j.ijcard.2014.11.182
  145. Cha MJ, Choi EK, Han KD, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke 2017;48:3040-8. https://doi.org/10.1161/STROKEAHA.117.018773
  146. Cho MY, Park J, Kim Y, et al. Clinical effectiveness and safety of standard-dose and low-dose non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a nationwide populationbased cohort study. Heart Rhythm 2017.
  147. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111:933-42. https://doi.org/10.1160/TH13-09-0734
  148. Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015;13:353-9. https://doi.org/10.1111/jth.12823
  149. Li CH, Liu CJ, Chou AY, et al. European Society of Cardiology guideline-adherent antithrombotic treatment and risk of mortality in Asian patients with atrial fibrillation. Sci Rep 2016;6:30734. https://doi.org/10.1038/srep30734
  150. Kim H, Kim TH, Cha MJ, et al. A prospective survey of atrial fibrillation management for real-world guideline adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry. Korean Circ J 2017;47:877-87. https://doi.org/10.4070/kcj.2017.0146
  151. Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GY. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study. PLoS One 2017;12:e0189495. https://doi.org/10.1371/journal.pone.0189495
  152. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016;14:1711-4. https://doi.org/10.1111/jth.13386
  153. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-33. https://doi.org/10.1056/NEJMoa1501035
  154. Douketis JD, Hasselblad V, Ortel TL. Bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2016;374:93-4.
  155. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-85. https://doi.org/10.1001/archinte.159.7.677
  156. Guo Y, Zhu H, Chen Y, Lip GY. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2018;131:185-92. https://doi.org/10.1016/j.amjmed.2017.09.009
  157. Chao TF, Lip GY, Lin YJ, et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol 2018;254:157-61. https://doi.org/10.1016/j.ijcard.2017.11.025
  158. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldan V, Lip GY, Marin F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thromb Haemost 2017;117:2261-6. https://doi.org/10.1160/TH17-10-0710
  159. Zulkifly H, Lip GY, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol 2017;120:1139-45. https://doi.org/10.1016/j.amjcard.2017.06.058
  160. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12. https://doi.org/10.1016/j.jacc.2014.04.029
  161. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42. https://doi.org/10.1016/S0140-6736(09)61343-X
  162. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013;127:720-9. https://doi.org/10.1161/CIRCULATIONAHA.112.114389
  163. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312:1988-98. https://doi.org/10.1001/jama.2014.15192
  164. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015;65:2614-23. https://doi.org/10.1016/j.jacc.2015.04.025
  165. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465-74. https://doi.org/10.1093/eurheartj/ehv730
  166. Badheka AO, Chothani A, Mehta K, et al. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume. Circ Arrhythm Electrophysiol 2015;8:42-8. https://doi.org/10.1161/CIRCEP.114.001413
  167. Casu G, Gulizia MM, Molon G, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. Eur Heart J Suppl 2017;19:D333-53. https://doi.org/10.1093/eurheartj/sux008
  168. Whitlock R, Healey J, Vincent J, et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann Cardiothorac Surg 2014.3:45-54.
  169. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997;29:135-40. https://doi.org/10.1016/S0196-0644(97)70319-6
  170. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174-9. https://doi.org/10.1097/CCM.0b013e3181a02f56
  171. Tisdale JE, Padhi ID, Goldberg AD, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J 1998;135:739-47. https://doi.org/10.1016/S0002-8703(98)70031-6
  172. Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222-30. https://doi.org/10.1111/acem.12091
  173. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-9. https://doi.org/10.1016/0002-9149(89)90141-0
  174. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991;18:891-7. https://doi.org/10.1016/0735-1097(91)90743-S
  175. Steinberg JS, Katz RJ, Bren GB, Buff LA, Varghese PJ. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-11. https://doi.org/10.1016/S0735-1097(87)80396-0
  176. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60. https://doi.org/10.1161/01.CIR.83.1.52
  177. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012;125:945-57. https://doi.org/10.1161/CIRCULATIONAHA.111.019935
  178. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-8. https://doi.org/10.1016/S0002-9149(97)00962-4
  179. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149-53. https://doi.org/10.1097/00003246-200106000-00011
  180. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73. https://doi.org/10.1056/NEJMoa1001337
  181. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760-73. https://doi.org/10.7326/M13-1467
  182. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77. https://doi.org/10.1056/NEJMoa0708789
  183. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238-46. https://doi.org/10.1016/S0140-6736(12)60570-4
  184. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015;(3):CD005049.
  185. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33. https://doi.org/10.1056/NEJMoa021328
  186. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40. https://doi.org/10.1056/NEJMoa021375
  187. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-86. https://doi.org/10.1378/chest.126.2.476
  188. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013;36:122-33. https://doi.org/10.1111/j.1540-8159.2012.03513.x
  189. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-62. https://doi.org/10.1001/archinte.165.3.258
  190. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med 2014;19:222-3. https://doi.org/10.1136/ebmed-2014-110062
  191. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333-40. https://doi.org/10.1001/jama.2009.2029
  192. Arbelo E, Brugada J, Hindricks G, et al. The atrial fibrillation ablation pilot study: a European survey on methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-78. https://doi.org/10.1093/eurheartj/ehu001
  193. Anselmino M, Matta M, D'Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014;7:1011-8. https://doi.org/10.1161/CIRCEP.114.001938
  194. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013;166:442-8. https://doi.org/10.1016/j.ahj.2013.05.015
  195. Shi LZ, Heng R, Liu SM, Leng FY. Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials. Exp Ther Med 2015;10:816-22. https://doi.org/10.3892/etm.2015.2545
  196. Choi YJ, Kang KW, Kim TH, et al. Comparison of rhythm and rate control strategies for stroke occurrence in a prospective cohort of atrial fibrillation patients. Yonsei Med J 2018;59:258-64. https://doi.org/10.3349/ymj.2018.59.2.258
  197. Kirchhof P, Monnig G, Wasmer K, et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005;26:1292-7. https://doi.org/10.1093/eurheartj/ehi160
  198. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:1282-7. https://doi.org/10.1161/01.CIR.101.11.1282
  199. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:1275-9. https://doi.org/10.1016/S0140-6736(02)11315-8
  200. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart 2015;101:1526-30. https://doi.org/10.1136/heartjnl-2015-307656
  201. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996;28:700-6. https://doi.org/10.1016/S0735-1097(96)00230-6
  202. Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152-5. https://doi.org/10.1016/j.hrthm.2008.10.036
  203. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-50. https://doi.org/10.1016/j.ehj.2003.10.020
  204. Hemels ME, Van Noord T, Crijns HJ, et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol 2006;48:1001-9. https://doi.org/10.1016/j.jacc.2006.05.043
  205. Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. Am Heart J 2000;140:e12.
  206. De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-4. https://doi.org/10.1016/S0735-1097(99)00256-9
  207. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997;18:649-54. https://doi.org/10.1093/oxfordjournals.eurheartj.a015311
  208. Atarashi H, Inoue H, Fukunami M, et al. Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 2002;66:553-6. https://doi.org/10.1253/circj.66.553
  209. Schadlich PK, Schmidt-Lucke C, Huppertz E, et al. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc Drugs 2007;7:199-217. https://doi.org/10.2165/00129784-200707030-00006
  210. Schmidt-Lucke C, Paar WD, Stellbrink C, et al. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for nonvalvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res 2007;119:27-34. https://doi.org/10.1016/j.thromres.2005.11.016
  211. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004;109:997-1003. https://doi.org/10.1161/01.CIR.0000120509.64740.DC
  212. Shin DG, Cho I, Hartaigh B, et al. Cardiovascular events of electrical cardioversion under optimal anticoagulation in atrial fibrillation: the multicenter analysis. Yonsei Med J 2015;56:1552-8. https://doi.org/10.3349/ymj.2015.56.6.1552
  213. Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015;17:18-23. https://doi.org/10.1093/europace/euu189
  214. Gwag HB, Chun KJ, Hwang JK, et al. Which antiarrhythmic drug to choose after electrical cardioversion: a study on non-valvular atrial fibrillation patients. PLoS One 2018;13:e0197352. https://doi.org/10.1371/journal.pone.0197352
  215. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121-8. https://doi.org/10.1016/S0167-5273(02)00467-9
  216. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255-62.
  217. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-85. https://doi.org/10.1001/archinte.163.7.777
  218. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;89:239-48. https://doi.org/10.1016/S0167-5273(02)00477-1
  219. Thomas SP, Guy D, Wallace E, et al. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J 2004;147:E3. https://doi.org/10.1016/S0002-8703(03)00526-X
  220. Vijayalakshmi K, Whittaker VJ, Sutton A, et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006;151:863.e1-6.
  221. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72. https://doi.org/10.1056/NEJMoa041705
  222. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25. https://doi.org/10.1161/CIRCULATIONAHA.107.723866
  223. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-9. https://doi.org/10.1161/CIRCEP.109.870204
  224. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-21. https://doi.org/10.1016/j.jacc.2010.07.046
  225. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-79. https://doi.org/10.1007/s10557-012-6374-4
  226. Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-24. https://doi.org/10.1016/j.ehj.2004.04.030
  227. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-21. https://doi.org/10.1161/01.CIR.94.7.1613
  228. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4. https://doi.org/10.1016/S0002-9149(98)00223-9
  229. Mun HS, Shen C, Pak HN, et al. Chronic amiodarone therapy impairs the function of the superior sinoatrial node in patients with atrial fibrillation. Circ J 2013;77:2255-63. https://doi.org/10.1253/circj.CJ-12-1615
  230. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-inthe-pocket” approach. N Engl J Med 2004;351:2384-91. https://doi.org/10.1056/NEJMoa041233
  231. Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Systematic review and costeffectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 2010.14:iii-iv.
  232. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation 2017;136:583-96. https://doi.org/10.1161/CIRCULATIONAHA.116.023163
  233. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-21. https://doi.org/10.1016/0002-9149(89)90574-2
  234. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8. https://doi.org/10.1056/NEJM199103213241201
  235. Chimienti M, Cullen MT Jr, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16:1943-51. https://doi.org/10.1093/oxfordjournals.eurheartj.a060852
  236. Kim DS, Koh CW, Cho HK, et al. Comparision of the efficacy of propafenone and flecainide in patients with atrial fibrillation. Korean Circ J 1997;27:860-6. https://doi.org/10.4070/kcj.1997.27.9.860
  237. Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011;13:161-73. https://doi.org/10.1093/europace/euq382
  238. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329-45. https://doi.org/10.1093/europace/euq450
  239. Chun KJ, Byeon K, Im SI, et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clin Ther 2014;36:1169-75. https://doi.org/10.1016/j.clinthera.2014.07.013
  240. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77-82. https://doi.org/10.1056/NEJM199507133330201
  241. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009;54:143-9. https://doi.org/10.1016/j.jacc.2009.03.043
  242. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4:1250-9. https://doi.org/10.1016/j.hrthm.2007.07.020
  243. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99. https://doi.org/10.1056/NEJMoa054686
  244. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78. https://doi.org/10.1056/NEJMoa0803778
  245. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87. https://doi.org/10.1056/NEJMoa0800456
  246. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76. https://doi.org/10.1056/NEJMoa1109867
  247. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-20. https://doi.org/10.1056/NEJM200003303421302
  248. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20. https://doi.org/10.1056/NEJM200105103441901
  249. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6. https://doi.org/10.1161/CIRCULATIONAHA.110.977546
  250. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006. https://doi.org/10.1016/j.jacc.2013.02.025
  251. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082-7. https://doi.org/10.1016/j.jacc.2013.09.062
  252. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346-55. https://doi.org/10.1093/eurheartj/ehu367
  253. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. https://doi.org/10.1016/S0140-6736(16)31474-X
  254. Ezekowitz MD, Pollack CV Jr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018;39:2959-71. https://doi.org/10.1093/eurheartj/ehy148
  255. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. https://doi.org/10.1093/eurheartj/ehy136
  256. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2018 [Epub ahead of print].
  257. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71. https://doi.org/10.1056/NEJM199812033392303
  258. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12. https://doi.org/10.1016/S0140-6736(06)68845-4
  259. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15. https://doi.org/10.1016/S0140-6736(12)62177-1
  260. Rubboli A, Faxon DP, Juhani Airaksinen KE, et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview. Thromb Haemost 2014;112:1080-7. https://doi.org/10.1160/th14-08-0681
  261. Choi HI, Ahn JM, Kang SH, et al. Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents. JACC Cardiovasc Interv 2017;10:1075-85. https://doi.org/10.1016/j.jcin.2017.02.028
  262. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. https://doi.org/10.1056/NEJMoa1708454
  263. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-34. https://doi.org/10.1056/NEJMoa1611594
  264. Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2018;39:1726-1735a. https://doi.org/10.1093/eurheartj/ehy162
  265. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
  266. Lopes RD, Vora AN, Liaw D, et al. An open-Label, 2 $\times$ 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J 2018;200:17-23. https://doi.org/10.1016/j.ahj.2018.03.001
  267. Vranckx P, Lewalter T, Valgimigli M, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J 2018;196:105-12. https://doi.org/10.1016/j.ahj.2017.10.009
  268. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129:1577-85. https://doi.org/10.1161/CIRCULATIONAHA.113.004834
  269. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-60. https://doi.org/10.1093/eurheartj/ehx419
  270. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:e275-444. https://doi.org/10.1016/j.hrthm.2017.05.012
  271. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407-11. https://doi.org/10.1093/europace/eut241
  272. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 2015;12:1162-8. https://doi.org/10.1016/j.hrthm.2015.02.028
  273. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-8. https://doi.org/10.1016/j.jacc.2013.11.039
  274. Kottmaier M, Bourier F, Pausch H, et al. Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures. Am J Cardiol 2018;121:445-9. https://doi.org/10.1016/j.amjcard.2017.11.015
  275. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805-11. https://doi.org/10.1093/eurheartj/ehv177
  276. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627-36. https://doi.org/10.1056/NEJMoa1701005
  277. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018;39:2942-55. https://doi.org/10.1093/eurheartj/ehy176
  278. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94. https://doi.org/10.1093/eurheartj/ehr342
  279. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012;21:429-35. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007
  280. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-30. https://doi.org/10.1093/eurheartj/ehs274
  281. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129:961-70. https://doi.org/10.1161/CIRCULATIONAHA.113.003628
  282. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2599-604. https://doi.org/10.2215/CJN.02400311
  283. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. https://doi.org/10.1016/S0140-6736(13)62343-0
  284. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol 2016;117:69-75. https://doi.org/10.1016/j.amjcard.2015.09.046
  285. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-507. https://doi.org/10.1093/europace/euv309
  286. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. https://doi.org/10.1056/NEJMoa1009638
  287. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. https://doi.org/10.1056/NEJMoa1107039
  288. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104. https://doi.org/10.1056/NEJMoa1310907
  289. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106. https://doi.org/10.1038/ki.2009.477
  290. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33. https://doi.org/10.1681/ASN.2009030319
  291. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-8. https://doi.org/10.2215/CJN.04550511
  292. Schwartzenberg S, Lev EI, Sagie A, Korzets A, Kornowski R. The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. Am J Cardiol 2016;117:477-82. https://doi.org/10.1016/j.amjcard.2015.10.065
  293. Potpara TS, Ferro CJ, Lip GY. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018;14:337-51. https://doi.org/10.1038/nrneph.2018.19
  294. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018;138:1519-29. https://doi.org/10.1161/CIRCULATIONAHA.118.035418
  295. Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GY. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 2018;72:838-53. https://doi.org/10.1016/j.jacc.2018.05.066
  296. Yu HY, Kim P, Jang TH, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation: a nationwide cohort study. Stroke 2018;49:2421-9. https://doi.org/10.1161/STROKEAHA.118.021387
  297. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075-80. https://doi.org/10.1161/01.STR.0000209239.71702.ce
  298. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015;132:194-204. https://doi.org/10.1161/CIRCULATIONAHA.114.013267
  299. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. https://doi.org/10.1016/S0140-6736(07)61233-1
  300. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612-7. https://doi.org/10.1016/j.amjmed.2005.02.022
  301. Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018;138:37-47. https://doi.org/10.1161/CIRCULATIONAHA.117.031658
  302. Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (age ${\geq}$ 85 years) Japanese patients with atrial fibrillation: the Fushimi AF registry. Chest 2016;149:401-12. https://doi.org/10.1378/chest.15-1095
  303. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864-72. https://doi.org/10.1093/eurheartj/ehu046
  304. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to age. Circ J 2014;78:1349-56. https://doi.org/10.1253/circj.CJ-13-1324
  305. Lin YC, Chien SC, Hsieh YC, et al. Effectiveness and safety of standard- and low-dose rivaroxaban in Asians with atrial fibrillation. J Am Coll Cardiol 2018;72:477-85. https://doi.org/10.1016/j.jacc.2018.04.084
  306. Joung B. Real-world data and recommended dosage of non-vitamin K oral anticoagulants for Korean patients. Korean Circ J 2017;47:833-41. https://doi.org/10.4070/kcj.2017.0158

Cited by

  1. Validation of Single Centre Pre-Mobile Atrial Fibrillation Apps for Continuous Monitoring of Atrial Fibrillation in a Real-World Setting: Pilot Cohort Study vol.21, pp.12, 2019, https://doi.org/10.2196/14909
  2. A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines vol.14, pp.2, 2019, https://doi.org/10.1371/journal.pone.0211695
  3. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265
  4. Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention vol.94, pp.4, 2019, https://doi.org/10.3904/kjm.2019.94.4.330
  5. Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease vol.8, pp.10, 2018, https://doi.org/10.3390/jcm8101624
  6. Homocysteine, interleukin-1β, and fasting blood glucose levels as prognostic markers for diabetes mellitus complicated with cerebral infarction and correlated with carotid intima-media thickness vol.19, pp.2, 2020, https://doi.org/10.3892/etm.2019.8326
  7. Female sex and stroke in atrial fibrillation: an intriguing relationship vol.15, pp.2, 2018, https://doi.org/10.1007/s11739-019-02169-2
  8. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use vol.13, pp.3, 2018, https://doi.org/10.1161/circoutcomes.119.005894
  9. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation vol.9, pp.7, 2018, https://doi.org/10.2217/cer-2019-0197
  10. Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study vol.9, pp.5, 2018, https://doi.org/10.3390/jcm9051485
  11. Development and psychometric testing of the self-care scale for patients with chronic atrial fibrillation (AF-SCS-10) vol.19, pp.7, 2018, https://doi.org/10.1177/1474515120920472
  12. Management of antithrombotic agents for gastrointestinal endoscopy vol.63, pp.11, 2018, https://doi.org/10.5124/jkma.2020.63.11.711
  13. The difference of burden of ectopic beats in different types of atrial fibrillation and the effect of atrial fibrillation type on stroke risk in a prospective cohort of patients with atrial fibrillati vol.10, pp.None, 2018, https://doi.org/10.1038/s41598-020-63370-4
  14. CHA 2 DS 2 -VASc score, cerebral small vessel disease, and frailty in older patients with atrial fibrillation vol.10, pp.1, 2020, https://doi.org/10.1038/s41598-020-75256-6
  15. Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy vol.76, pp.6, 2020, https://doi.org/10.4166/kjg.2020.142
  16. What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg? vol.27, pp.None, 2018, https://doi.org/10.1177/10760296211061148
  17. Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management vol.16, pp.None, 2018, https://doi.org/10.15420/ecr.2020.43
  18. Effectiveness of Direct Oral Anticoagulants in Obese Adults With Atrial Fibrillation: A Systematic Review of Systematic Reviews and Meta-Analysis vol.8, pp.None, 2018, https://doi.org/10.3389/fcvm.2021.732828
  19. Esophageal Endoscopy after High-power and Short-duration Ablation in Atrial Fibrillation Patients vol.51, pp.2, 2021, https://doi.org/10.4070/kcj.2020.0488
  20. Left Atrial Enlargement and Sick Sinus Syndrome for Pacemaker Indication Were Associated with Atrial High Rate Episodes vol.51, pp.3, 2021, https://doi.org/10.4070/kcj.2020.0515
  21. Clinical outcomes among hemodialysis patients with atrial fibrillation: a Korean nationwide population-based study vol.40, pp.1, 2018, https://doi.org/10.23876/j.krcp.20.022
  22. Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study vol.18, pp.5, 2018, https://doi.org/10.1016/j.hrthm.2021.01.016
  23. Beginning the Journey to Find Optimal Antithrombotic Regimens for Korean Patients with Atrial Fibrillation after Percutaneous Coronary Intervention vol.51, pp.5, 2018, https://doi.org/10.4070/kcj.2021.0017
  24. Integrated care and outcomes in patients with atrial fibrillation and comorbidities vol.51, pp.6, 2021, https://doi.org/10.1111/eci.13498
  25. Individualized education focusing on self‐management improved the knowledge and self‐management behaviour of elderly people with atrial fibrillation: A randomized controlled trial vol.27, pp.4, 2018, https://doi.org/10.1111/ijn.12902
  26. Association of cardiovascular health and incident atrial fibrillation in elderly population vol.107, pp.15, 2021, https://doi.org/10.1136/heartjnl-2020-318858
  27. Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study vol.121, pp.9, 2018, https://doi.org/10.1055/a-1336-0476
  28. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation vol.7, pp.5, 2018, https://doi.org/10.1093/ehjcvp/pvab004
  29. The 2021 Korean Heart Rhythm Society Guidelines for a New Approach and Integrated Management of Atrial Fibrillation vol.96, pp.5, 2018, https://doi.org/10.3904/kjm.2021.96.5.382
  30. Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution vol.14, pp.None, 2021, https://doi.org/10.21518/2079-701x-2021-14-68-76
  31. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice vol.10, pp.22, 2018, https://doi.org/10.3390/jcm10225337
  32. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation vol.37, pp.6, 2021, https://doi.org/10.1002/joa3.12652
  33. Use of direct oral anticoagulants does not significantly increase delayed bleeding after endoscopic submucosal dissection for early gastric neoplasms vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-88656-z
  34. Risk for osteoporotic fractures in patients with atrial fibrillation using different oral anticoagulants vol.22, pp.1, 2021, https://doi.org/10.1186/s42444-021-00032-0